JP2008505054A - Ｉｌ−６アンタゴニストで骨関節炎を治療する方法 - Google Patents

Ｉｌ−６アンタゴニストで骨関節炎を治療する方法 Download PDF

Info

Publication number
JP2008505054A
JP2008505054A JP2006552709A JP2006552709A JP2008505054A JP 2008505054 A JP2008505054 A JP 2008505054A JP 2006552709 A JP2006552709 A JP 2006552709A JP 2006552709 A JP2006552709 A JP 2006552709A JP 2008505054 A JP2008505054 A JP 2008505054A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
human
osteoarthritis
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505054A5 (enExample
Inventor
ボーヴ，スーザン・エリザベス
キルゴア，ケニース・スタンレー
Original Assignee
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008505054(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー filed Critical ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー
Publication of JP2008505054A publication Critical patent/JP2008505054A/ja
Publication of JP2008505054A5 publication Critical patent/JP2008505054A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006552709A 2004-02-11 2005-01-31 Ｉｌ−６アンタゴニストで骨関節炎を治療する方法 Pending JP2008505054A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54381404P 2004-02-11 2004-02-11
PCT/IB2005/000240 WO2005080429A2 (en) 2004-02-11 2005-01-31 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies

Publications (2)

Publication Number Publication Date
JP2008505054A true JP2008505054A (ja) 2008-02-21
JP2008505054A5 JP2008505054A5 (enExample) 2008-04-10

Family

ID=34885980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552709A Pending JP2008505054A (ja) 2004-02-11 2005-01-31 Ｉｌ−６アンタゴニストで骨関節炎を治療する方法

Country Status (9)

Country Link
US (2) US20080145367A1 (enExample)
EP (1) EP1715891B2 (enExample)
JP (1) JP2008505054A (enExample)
AT (1) ATE464908T1 (enExample)
BR (1) BRPI0506679A (enExample)
CA (1) CA2555688C (enExample)
DE (1) DE602005020743D1 (enExample)
ES (1) ES2341461T5 (enExample)
WO (1) WO2005080429A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507434A (ja) * 2011-02-08 2014-03-27 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
WO2008019061A2 (en) 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
RU2565809C2 (ru) * 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2016044153A1 (en) * 2014-09-18 2016-03-24 Rush University Medical Center Methods for preventing or treating osteoarthritis
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
AU2016302768B2 (en) 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208514A (ja) * 1994-10-07 1996-08-13 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分とする慢性関節リウマチ治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT52962A (en) * 1988-03-04 1990-09-28 Sandoz Ag Process for production of medical compositions eliminating bone-absorption and promoting forming of bones
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5617790A (en) * 1995-05-31 1997-04-08 P.R. Graphics Limited Apparatus for producing flexographic printing plates
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208514A (ja) * 1994-10-07 1996-08-13 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分とする慢性関節リウマチ治療剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507434A (ja) * 2011-02-08 2014-03-27 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療

Also Published As

Publication number Publication date
WO2005080429A3 (en) 2006-02-23
CA2555688A1 (en) 2005-09-01
BRPI0506679A (pt) 2007-05-15
EP1715891A2 (en) 2006-11-02
US20100215654A1 (en) 2010-08-26
ES2341461T3 (es) 2010-06-21
DE602005020743D1 (de) 2010-06-02
EP1715891B2 (en) 2014-08-13
US20080145367A1 (en) 2008-06-19
WO2005080429A2 (en) 2005-09-01
ES2341461T5 (es) 2014-10-29
ATE464908T1 (de) 2010-05-15
CA2555688C (en) 2011-11-08
EP1715891B1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
EP1715891B1 (en) Methods of treating osteoarthritis with anti-il-6 antibodies
KR102687412B1 (ko) 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도
CN108337890B (zh) 新型pd-1免疫调节剂
KR102502640B1 (ko) Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
KR101811886B1 (ko) 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
JP4468172B2 (ja) 単球走化性タンパク質−１（ｍｃｐ−１）に対する抗体、およびその使用
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
TWI307716B (en) Dual specificity antibodies and methods of making and using
CN111789944A (zh) 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
KR20090059161A (ko) 글루카곤 수용체 항체에 관한 조성물 및 방법
CN111662379A (zh) 抗新型冠状病毒的抗体、制备方法和应用
CN114507282A (zh) 人单克隆抗-pd-l1抗体和使用方法
CN102281898B (zh) Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
KR20160113208A (ko) 항-트랜스티레틴 인간 항체
KR20200128125A (ko) 신체 조성을 변경하기 위한 방법
US20240199732A1 (en) Anti-IL-27 Antibodies and Uses Thereof
US20040214761A1 (en) Method for treating multiple myeloma
KR100988129B1 (ko) 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
CN113227130A (zh) 抗体及其用途
WO2025167705A1 (zh) 一种抗tl1a抗体及其制备方法和用途
CN114685653A (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
WO2019136516A1 (en) Methods of treating myocarditis and/or cardiomyopathy and reagents therefor
MXPA06007963A (es) Metodos para el tratamiento de la osteoartritis con anticuerpos anti-il-6 o del receptor anti-il-6
WO2021000004A1 (en) Methods of treating myocarditis and/or cardiomyopathy and reagents therefor
CA3287909A1 (en) Anti-tl1a antibody, preparation method therefor and use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080221

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090126

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110418